title: PGE1 or PGE2 not LH regulates secretion of progesterone in vitro by the 88-90 day ovine corpus luteum of pregnancy.
abstract: Secretion of progesterone in vitro by mature day 8 ovine corpora lutea (CL) of the estrous cycle was increased linearly by ovine LH (1, 10 and 100 ng/ml) or prostaglandin E2 (PGE2) 1, 10 and 100 ng/ml) in a dose dependent manner (P < or = 0.05). Progesterone secretion in vitro by 88-90 day ovine CL of pregnancy was not affected P > or = 0.05 by LH (1, 10 and 100 ng/ml) while prostaglandin E1 (PGE1) 1, 10 and 100 ng/ml) increased (P < or = 0.05) secretion of progesterone in a dose dependent manner and PGE2 (1, 10 and 100 ng/ml) increased (P < or = 0.05) secretion of progesterone only at the 100 ng/ml dose. Day 8 ovine CL of the estrous cycle did not secrete (P > or = 0.05) detectable quantities of prostaglandin F2 alpha (PGF2 alpha) or prostaglandin E (PGE) while 88-90 day ovine CL of pregnancy secrete PGE (P < or = 0.05) but not PGF2 alpha (P > or = 0.05). Regulation of PGE secretion by 88-90 day ovine CL of pregnancy may be via pregnancy specific protein B (PSPB), which increased (P < or = 0.05) PGE and progesterone but not PGF2 alpha (P > or = 0.05) secretion. Secretion of progesterone by CL of 88-90 days of pregnancy was not affected by IGF1, IGF2, PAF-16, PAF-18, oxytocin, PGI2, PGD2 or leukotriene C4 (P > or = 0.05). It is concluded that PGE1 or PGE2 but not LH regulates secretion of progesterone in vitro by 88-90 day ovine CL of pregnancy. In addition, it is concluded that 88-90 day ovine CL of pregnancy secretes it's own luteotropin, which is PGE. Secretion of PGE by ovine CL of pregnancy may be regulated by PSPB.
authors.affiliation: Department of Animal Sciences, University of Hawaii, Honolulu 96822, USA.
authors.forename: Y S
authors.initials: YS
authors.lastname: Weems
authors.forename: P J
authors.initials: PJ
authors.lastname: Bridges
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: R G
authors.initials: RG
authors.lastname: Sasser
authors.forename: B R
authors.initials: BR
authors.lastname: LeaMaster
authors.forename: D L
authors.initials: DL
authors.lastname: Vincent
authors.forename: C W
authors.initials: CW
authors.lastname: Weems
mesh_terms: D000527:Alprostadil / Q000494:pharmacology*; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000494:pharmacology; D003338:Corpus Luteum / Q000187:drug effects / Q000378:metabolism*; D015237:Dinoprost / Q000378:metabolism; D015232:Dinoprostone / Q000494:pharmacology*; D004971:Estrus / Q000502:physiology; D005260:Female; D066298:In Vitro Techniques; D007986:Luteinizing Hormone / Q000494:pharmacology*; D009929:Organ Size; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000494:pharmacology; D011270:Pregnancy, Animal / Q000502:physiology*; D011374:Progesterone / Q000378:metabolism*; D012756:Sheep
chemical_list: D011257:Pregnancy Proteins; D011374:Progesterone; D007986:Luteinizing Hormone; D015237:Dinoprost; D016282:Aspartic Acid Endopeptidases; C094766:pregnancy-associated glycoprotein 1; D000527:Alprostadil; D015232:Dinoprostone